Eplerenone Therapy After Myocardial Infarction in Patients With Reduced Ejection Fraction

Patient Selection

• Eligibility requires left‑ventricular ejection fraction ≤40 % measured after the acute infarction, presence of clinical heart‑failure signs (e.g., pulmonary congestion, S3 gallop, Killip ≥ II) or a diagnosis of diabetes mellitus, and receipt of optimized ACE‑inhibitor (or ARB) + beta‑blocker therapy at target doses. This aligns with the 2025 ACC/AHA guideline criteria. 1
• The drug should be initiated when the patient is clinically stable between days 3 and 14 after the myocardial infarction. 2

Contraindications

• Baseline serum potassium >5.0 mmol/L precludes eplerenone use. 1
• Serum creatinine >2.5 mg/dL in males or >2.0 mg/dL in females (or equivalent eGFR < 30 mL/min/1.73 m²) is an absolute contraindication, reflecting exclusion criteria of the pivotal trial. 1

Dosing and Administration

• If potassium rises to 5.0–5.4 mmol/L, reduce dose to 25 mg daily or every other day; if 5.5–5.9 mmol/L, withhold and restart at 25 mg every other day once potassium <5.0 mmol/L; if ≥6.0 mmol/L, discontinue permanently. (Protocol derived from trial safety monitoring.) 1

Monitoring Protocol

• Serum potassium and creatinine should be checked at 3 days, 1 week, 1 month, 2 months, and then every 3 months after starting eplerenone. This schedule is recommended to prevent hyper‑kalemia‑related events. 3

Evidence of Benefit

• The EPHESUS randomized trial (6,632 patients) demonstrated a 15 % relative reduction in all‑cause mortality and a 13 % relative reduction in the composite of cardiovascular death or heart‑failure hospitalization when eplerenone was added to standard therapy. Benefits were evident within 30 days of initiation. 1
• 86 % of trial participants were already on ACE‑inhibitor/ARB and 75 % on beta‑blockers, confirming that eplerenone provides incremental mortality benefit beyond optimal background therapy. 1
• A post‑hoc analysis showed that initiating eplerenone earlier than 7 days post‑MI further reduced sudden cardiac death and cardiovascular mortality compared with later initiation. 2

Guideline Strength

• The 2025 ACC/AHA guideline assigns a Class I recommendation (should be given) with Level B evidence for eplerenone in the defined post‑MI population. 1

Practical Considerations

• Eplerenone must be added to, not replace, ACE‑inhibitor/ARB + beta‑blocker therapy; monotherapy is contraindicated. 1
• Concurrent use of ACE‑inhibitor + ARB + eplerenone is discouraged because it increases adverse events without additional benefit. 1
• Patients with advanced chronic kidney disease (baseline creatinine >2.5 mg/dL) were excluded from the pivotal trial and are at high risk for hyper‑kalemia; eplerenone should not be prescribed in this group. 1

Eplerenone Use in Congestive Heart Failure

Indications and Evidence Base

• The European Society of Cardiology recommends eplerenone for patients with heart failure with reduced ejection fraction (HFrEF), particularly those with NYHA class II-IV symptoms, EF ≤35-40%, and already receiving an ACE inhibitor and beta-blocker 4
• In the EPHESUS Trial, eplerenone reduced all-cause mortality by 15% and cardiovascular death or hospitalization by 13% in 6,632 patients with EF <40% and clinical HF signs after MI 4
• In the EMPHASIS-HF Trial, eplerenone reduced the composite endpoint of cardiovascular death or HF hospitalization by 37%, all-cause mortality by 24%, and HF hospitalization alone by 42% in 2,737 patients with NYHA class II symptoms and EF ≤30% (or ≤35% with QRS >130ms) 4

Specific Patient Criteria

• The American Heart Association recommends that eplerenone be prescribed for CHF patients who meet ALL of the following: EF ≤35-40%, NYHA functional class II-IV symptoms, already receiving optimal doses of ACE inhibitor (or ARB) AND beta-blocker 4, 5

Mandatory Monitoring Protocol

• The European Society of Cardiology recommends checking serum potassium and creatinine at specific intervals to prevent life-threatening hyperkalemia, including before initiation, within the first week after starting, and at 1, 2, 3, and 6 months after achieving maintenance dose 4, 6

Absolute Contraindications

• The American College of Cardiology recommends not prescribing eplerenone if serum creatinine >2.5 mg/dL in men or >2.0 mg/dL in women (for post-MI patients) 5

Critical Management Points

• The European Heart Journal recommends that if creatinine rises to >220 μmol/L (2.5 mg/dL), halve the eplerenone dose immediately; if it rises to >310 μmol/L (3.5 mg/dL), stop eplerenone completely and monitor blood chemistry closely 6

Common Pitfalls to Avoid

• The American Heart Association recommends not using eplerenone as monotherapy—it must be added to optimized ACE inhibitor/ARB and beta-blocker therapy 4, 5